

Amendments to the Specification:

Please replace the Cross Reference to Related Applications Section (paragraph 1 on page 1) with the following amended paragraph:

This application is the National Stage of International Application No. PCT/US99/26133, filed November 5, 1999, which takes priority from United States provisional Patent Application No. 60/107,404, filed November 6, 1998.

Please replace paragraph 2 on page 48, lines 13-22, with the following amended paragraph:

Tables 3-5 show the activity expressed as Vmax values (milliAbsorbance(OD) units/minute at 405 nm) for 3 different clones of the mAb (K2.F1.1, K2.F1.3 and K2.F1.6) and a non-producing clone used as a negative control (K2.A12). Table 3 shows the results for wells coated with 1 μ g OVA-unoxCAP 37. Table 4 shows the results for wells coated with 1 μ g OVA-oxCAP 37. Table 5 shows the results for wells coated with 1 μ g PAox OVA. No activity was seen using the unoxidized CAP-37 polypeptide conjugated to OVA (Table 3), but, surprisingly, very little activity was observed when the oxidized CAP-37-OVA conjugate was used in the screen (Table 4). Figure 11 shows the template of a 96-well plate used in obtaining the data of Tables 3-5. The cell line K2.F1.6 was deposited with the American Type Culture Collection (ATCC) 10801 University Blvd., Manassas, VA, 20110-2209 on October 29, 1999, and assigned Patent Deposit Number PTA-897.